Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice Egerton

Showing results (1-10 of 99) with videos related to

Pageof 10
Sort By:
Psychopharmacology|September 6, 2019
The potential of <sup>1</sup>H-MRS in CNS drug developmentAlice Egerton
Current Pharmaceutical Biotechnology|January 31, 2012
The glutamate hypothesis of schizophrenia: neuroimaging and drug developmentAlice Egerton, James M Stone
Frontiers in Psychiatry|December 11, 2013
Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in PsychosisKate Merritt, Philip McGuire, Alice Egerton
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 7, 2005
Acute delta9-tetrahydrocannabinol-induced deficits in reversal learning: neural correlates of affective inflexibilityAlice Egerton, Ros R Brett, Judith A Pratt
Current Pharmaceutical Design|January 14, 2012
Glutamate and psychosis riskAlice Egerton, Paolo Fusar-Poli, James M Stone
Psychopharmacology|July 4, 2008
Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the ratAlice Egerton, Rabia Ahmad, Ella Hirani, et al.
Psychological Medicine|February 19, 2021
Demographic and clinical variables associated with response to clozapine in schizophrenia: a systematic review and meta-analysisKira Griffiths, Edward Millgate, Alice Egerton, et al.
Neuroscience and Biobehavioral Reviews|April 1, 2006
Cannabinoids and prefrontal cortical function: insights from preclinical studiesAlice Egerton, Claire Allison, Ros R Brett, et al.
Scientific Reports|November 25, 2025
Glutamate, NAA, and energy metabolism in clinical high risk and first episode psychosisBridget King, Matthew J Kempton, Shue Kit Man, et al.
BMC Psychiatry|January 15, 2017
Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic reviewAmy L Gillespie, Ruta Samanaite, Jonathan Mill, et al.
Pageof 10

Showing results (1-10 of 99) with videos related to

Sort By:
Pageof 10
Psychopharmacology|September 6, 2019
The potential of <sup>1</sup>H-MRS in CNS drug developmentAlice Egerton
Current Pharmaceutical Biotechnology|January 31, 2012
The glutamate hypothesis of schizophrenia: neuroimaging and drug developmentAlice Egerton, James M Stone
Frontiers in Psychiatry|December 11, 2013
Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in PsychosisKate Merritt, Philip McGuire, Alice Egerton
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 7, 2005
Acute delta9-tetrahydrocannabinol-induced deficits in reversal learning: neural correlates of affective inflexibilityAlice Egerton, Ros R Brett, Judith A Pratt
Current Pharmaceutical Design|January 14, 2012
Glutamate and psychosis riskAlice Egerton, Paolo Fusar-Poli, James M Stone
Psychopharmacology|July 4, 2008
Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the ratAlice Egerton, Rabia Ahmad, Ella Hirani, et al.
Psychological Medicine|February 19, 2021
Demographic and clinical variables associated with response to clozapine in schizophrenia: a systematic review and meta-analysisKira Griffiths, Edward Millgate, Alice Egerton, et al.
Neuroscience and Biobehavioral Reviews|April 1, 2006
Cannabinoids and prefrontal cortical function: insights from preclinical studiesAlice Egerton, Claire Allison, Ros R Brett, et al.
Scientific Reports|November 25, 2025
Glutamate, NAA, and energy metabolism in clinical high risk and first episode psychosisBridget King, Matthew J Kempton, Shue Kit Man, et al.
BMC Psychiatry|January 15, 2017
Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic reviewAmy L Gillespie, Ruta Samanaite, Jonathan Mill, et al.
Pageof 10